Introduction
It is well known today that a large portion of the human genome ($70%) is transcribed and that the majority of the produced transcripts are noncoding (ENCODE or FANTOM consortia). [1] [2] [3] [4] Among the 200,000 known transcripts, around 28,000 stem from long noncoding ribonucleic acid (lncRNA) loci (GENCODE). 5 Genome-wide association studies (GWAS) recurrently find disease-linked genetic variation in the nonprotein-coding sequence space, 6 often overlapping gene regulatory elements like enhancers, which are actively transcribed and give rise to noncoding RNAs. 7, 8 Concurrently, transcriptomic analyses in patient cohorts reveal numerous lncRNAs which are differentially expressed in diseased tissues. Recent work has shown that many lncRNAs are functional, leading to the notion that lncRNAs may represent a large class of potential therapeutic agents and targets. In this minireview, we describe lncRNAs linked to atherosclerosis in humans which are expressed in cells of the arterial wall (wall endothelial cells [ECs] , vascular smooth muscle cells [VSMCs] , and circulating and resident immune cells). We do not cover the roles of lncRNAs regulating atherosclerosis risk factors, such as lipid metabolism, diabetes, or hypertension, or adaptation to ischemic stress. We describe molecular roles of relevant disease-linked lncRNAs, and techniques to therapeutically manipulate them at the RNA level, referred to as RNA therapeutics, an approach that focuses on controlling RNA form and sequence without affecting the deoxyribonucleic acid (DNA) in our genomes. abundance are regulated and are cell-type specific. Both linear and circular lncRNAs have been shown to be overall functional in one pathway or another. lncRNAs effector mechanisms are diverse and complex (►Fig. 1B), making it nontrivial to decide which one to interfere with for therapy:
(1) lncRNAs guide, scaffold, and control transcriptionregulating protein complexes:
Many lncRNAs are known to affect transcription of RNAP I and II target genes, often by impacting chromatin readers and writers in gene promoter control. 11 Examples with relevance for atherosclerosis are ANRIL, H19, lincRNA-p21, MALAT1, MEG3, NEAT1, or TUG1 (►Table 2). lncRNAs affect transcription in cis, or also in trans, especially if their steadystate abundance is large and allows diffusion of the lncRNA throughout the nucleoplasm. Mechanistically, lncRNAs can recruit chromatin remodelers to target genes via hybridization to DNA, or control their enzymatic activity, or function as negative decoys. lncRNAs can also regulate the transcription of microRNA and other noncoding RNAs (a process distinct from RNA sponging, see 5).
(2) Enhancer RNAs/eRNAs: Active enhancers for gene promoters have recently been found to be transcribed and to give rise to enhancer lncRNAs (eRNAs). These can confer enhancer activity by capturing the promoter-contacting Mediator protein complex. 12 Examples of eRNAs important for atherosclerosis are HOTTIP, LEENE, and SMILR (►Table 2). Depending on enhancer, both, the eRNA and the chromatin-opening during transcription of the eRNA locus can be therapeutically relevant. 11 (3) Antisense lncRNAs/asRNAs: Some lncRNA genes reside within protein-coding gene units, even overlapping coding exons in antisense. Effects on host genes can be positive and negative. Examples with relevance for atherosclerosis are ANRIL, HOXC-AS1, MALAT1, and SENCR (►Table 2). Globally, antisense transcription dampens transcriptional noise and is not part of signaldependent expression control. 13 Therapeutic programming through asRNAs is complex, because it may require engineering the genomic locus.
(4) LncRNAs in subnuclear bodies: Some lncRNAs can affect other genes through their architectural role in assembling eu-and heterochromatin subnuclear territories. Examples are MALAT1 in Polycomb bodies, 14 or NEAT1 in paraspeckles. 15 These indirectly affect gene expression and pre-messenger RNA (mRNA) processing, respectively, depending on the vicinity of genes to these subnuclear bodies. The broadness of the effect and the complexity of the process make it difficult to achieve specificity in therapy.
(5) lncRNAs as microRNA sponge: Although many publications implicate endogenous lncRNAs as microRNA sponges (and as inhibitors of microRNA availability and function, therein), many of these reports are met with criticism because evidence often bases on uncontrolled lncRNA overexpression. Few lncRNAs pass the stoichiometric requirements for sponging, though, as most are endogenously not sufficiently highly expressed compared with the number of corresponding microRNA targets and copy numbers of microRNAs per cell (see Ref. 16 for overview).
(6) lncRNAs which bind and regulate proteins:
Mass spectrometric analyses showed that a single lncRNA can bind dozens of different proteins in the nucleus and in the cytoplasm, and thereby affect multiple molecular mechanisms at once 17 : This concept is best seen for wellstudied lncRNAs like XIST, which was found to bind > 80 proteins, indicating that it participated in DNA and histone modification and RNA remodeling machineries. 17 With relevance to atherosclerosis, circular ANRIL (circANRIL) binds to the rRNA processing PeBoW complex for protein translation control, 18 whereas linear ANRIL interacts with members of the PRC1 19 as well as with the PRC2 Polycomb-repressive complexes [19] [20] [21] during presumptive transcription control of target genes (►Table 2). In another case, TUG1 can serve as competing endogenous RNA, and also promote gene activity by chromatin fiber positioning, 14 and was even suggested to regulate cytoskeletal contractility by enhancing the cytoplasmic activity of Ezh2 toward methylating α-actin 22, 23 (►Table 2). Conceptually, a lncRNA may also hierarchically regulate a single transcriptional regulator, thereby influencing, in one step, a range of downstream genes and cellular processes. For example, NRON participates in scaffolding and restraining the nuclear factor of activated T cell (NFAT) transcription factor in a latently active form in the cytoplasm in unstimulated resting T cells. 24, 25 Transcription factor control is recurrently ascribed to many lncRNAs (►Table 2). Together, there is potential for lncRNAs in tuning protein complex activity as "RNA-drugs," akin to smallmolecule drugs, but lncRNA-dependent activity changes in lncRNA:protein complexes are difficult to study, and so far not understood in any case in mechanistic and structural detail. The clear separation between coding and noncoding RNA is blurring and some mRNAs carry functions also as untranslated RNAs. For example, the steroid receptor RNA, which is in principle protein-coding, also functions as lncRNA-in chromatin regulation at specific target genes in the nucleus. 27, 28 And p53, as noncoding RNA, binds and affects the activity of the MDM2 enzyme through structural RNA motifs. 29 In another more indirect case, under stress cohorts of several hundred mRNAs become transcribed from alternative upstream transcription start sites, a process that blocks their transcription from the actual promoters. This shift leads to a novel longer RNA isoforms that include a short upstream ORFs with a new stop codon, whose translation blocks the translation of the actual functional protein encoded in a given locus. 30 Thereby, functionality lies less in an active role as cis/trans-acting noncoding RNA, but more in indirect effects of translation control on the proteome. 31, 32 These findings expand the operational space for noncoding RNA therapeutics (►Table 1).
Known Roles of lncRNAs in Atherosclerosis
Limiting our review to those lncRNAs expressed in the vascular wall and functioning in atherosclerosis, 31 lncRNAs have so far been implicated in vascular cell types (►Table 2). Most were initially found because of being differentially expressed in patient cohorts. Only a few (ANRIL, circANRIL, MIAT, H19, LINC00305), were identified by unbiased GWAS. Fifteen of the listed lncRNAs were studied in immune cell types (such as peripheral blood monocytes, circulating and vascular wall macrophages, or foam cells), 17 in ECs, and 13 in VSMCs.
In the following, we highlight lncRNAs from ►Table 2 where in vivo evidence for therapeutic potential exists. Four groups may be distinguished: (1) lncRNAs with a documented therapeutic benefit for atherosclerosis, (2) lncRNAs with a benefit for other vascular diseases, (3) lncRNAs essential for normal vascular biology, and (4) lncRNAs generally involved in inflammatory signaling (with expected relevance for atherosclerosis).
1. In vivo evidence for therapeutic a potential in atherosclerosis has been determined only for one lncRNA: Neat1, a wellknown lncRNA, 76 is upregulated in plaques, and knockingout Neat1 in mice decreased neointimal lesions in an atherosclerosis model. 64 Since a full-body mouse knockout was analyzed, it remained unclear in which cell type Neat1 functioned. 64 A function in VSMCs was tested in vitro:
During carotid artery injury, VSMCs usually dedifferentiate from a quiescent to a proliferative/synthetic phenotype, and Neat1 promoted this atherogenic switch by repressing the function of the chromatin activator WDR5/MLL on serum response factor (SRF) target genes. 64 Consequently, therapeutically reducing NEAT1 in VSMCs in lesions might be useful for antagonizing the proatherogenic myocardin-SRF-dependent phenotypic switching of VSMCs, 64, 77 or the proatherogenic oxidized low-density lipoprotein (ox-LDL)dependent inflammatory signaling in macrophages. 78 However, given that VSMC proliferation and matrix synthesis are in other contexts also considered beneficial (for example, for plaque repair or for fibrous cap stability) (see Ref. 79 for review), more work is needed before NEAT1 can be considered for cell-type-specific therapy. 2. Three lncRNAs showed therapeutic potential at least regarding other vascular diseases: Downregulation of H19 ameliorates aneurysms, 38 and downregulation of Miat, 62 circHipk3, 33 or cZNF609 34 ameliorates diabetic retinopathy. 3. Two lncRNAs, MeXis 61 and Malat1, 57, 80, 81 have been studied by knockouts in mice. Nevertheless, the therapeutic potential of these lncRNAs remains untested: In the first case, MeXis levels were found to increase by ox-LDL stimulation of macrophages, upon which this lncRNA induced the Abca1 transporter and cholesterol efflux. 61 Since knockout of MeXis led to increased plaque growth in bone marrow reconstitution experiments of ldlr À/À mice, therapeutically increasing MeXis (human TCONS00016111) expression, especially in patients with single-nucleotide polymorphisms (SNPs) in this gene, 61 might potentially be therapeutically relevant. Care is advised, however, when interpreting data for Malat1, which has opposing roles in different cardiovascular conditions: On the one hand, MALAT1 was found to be downregulated in the plaque, 55 and knocking- out Malat1 in mice was recently found to trigger immune dysregulation and atherosclerosis in an apoe À/À mutant background, remarkably even without the challenge by a coronary artery disease-triggering fat-rich diet. 81 With a similar direction of effect, Malat1 knockouts developed larger infarcts in brain ischemic mouse models. 82, 83 These two studies suggested that it might be worthwhile to normalize MALAT1 through overexpression during therapy. Yet, in other contexts, such as aortic thoracic aneurysms or vascular diseases of the Marfan syndrome, beneficial effects seemed to lie rather in MALAT1 inhibition, and not in its induction. 57 Also, bluntly overexpressing Malat1 may have limitations because it is known from other studies that increases in MALAT1 would promote cancer by effects on cell migration, metastasis, and angiogenesis in hypoxic conditions. 84, 85 Summarizing, different studies showed context-and cell type-dependent therapeutic requirements for MALAT1. Consequently, further studies and tools for achieving tissue tropism in delivering therapeutic lncRNA only to specific cells, or for conditional activation/ inactivation of lncRNAs in specific conditions and cells, will be required. 
Translating Molecular Function to Therapeutic Value
In the following, we summarize key therapeutic principles centered on lncRNAs (►Fig. 2A). Thereby, we distinguish (1) therapeutic approaches exploiting endogenous lncRNA functionality, and (2) approaches based on artificial (nonnative) designer lncRNAs.
Disease Therapy by Manipulating Endogenous lncRNAs
During the onset of disease, lncRNAs expression levels change in cell-and context-dependent modes. For therapy, lncRNAs that are overactive in disease can be normalized by knockdown approaches. Gain-of-function approaches or RNA sequence correction can be used to antagonize disease-linked changes at the RNA level in other lncRNAs.
(1) Transcriptional control is, so far, the major known function of noncoding RNAs. Twenty-one of 31 atherosclerosis-linked lncRNAs function as guides, scaffolds, and regulators of chromatin factors (►Table 2). In contrast to small-molecule drugs which inhibit broadly-acting chromatin factors (such as DNA/histone methyltransferases, demethylases, acetylases, and chromatin readers), 86 epigenetic therapy through manipulating lncRNA levels and sequence may have the advantage that it allows, in principle, to sequence-specifically control specific subsets of target genes. Separately, it becomes a therapeutic option to guide generic repressor proteins (KRAB-and Chromo-domains) or activators (VP16) to promoters of disease-linked genes via noncoding RNAs. 87, 88 (2) Controlling splicing is equally important for therapy as transcription control. Splice-regulating antisense oligonucleotides (ASOs) can be used to tune splicing in mRNAs and lncRNAs. Additionally, a new therapeutic front was opened when it was found that cotranscriptional circRNA biogenesis interfered with linear RNA biogenesis. [89] [90] [91] A well-studied case is ANRIL, transcribed from Chr9p21 in humans, the most prominent atherosclerosis risk loci known so far. 18, 92 Linear ANRIL levels positively correlate with atherosclerosis severity, while circANRIL levels anticorrelate with atherosclerosis. 18, 21 While linear ANRIL expression causes transitions reminiscent of atherogenesis (inflammation, overproliferation, adhesion in macrophages and VSMCs), 19-21,93-95 circANRIL mediates opposite effects by blocking proliferation and enhancing cell death rates. 18 Thus, one way to decrease atherosclerosis risk would be to coincidently decrease linear ANRIL and increase circANRIL, because linear splice forms are known to be increased and circular isoforms decreased in atherosclerosis. How to therapeutically re-engineer the wildtype splicing pattern in a locus is highly complex, as learned from diseases like muscular dystrophies that arise from splicing defects (see Ref. 96 for a recent review), and it has not yet been practically achieved to simultaneously correct levels of linear and circular ANRIL. Theoretically, and confined to RNA-centric approaches, it would be possible to deliver in vitro produced synthetic circANRIL together with ASOs that target exonic ANRIL sequences that are not contained in the circular isoforms. Other options would be to use splice-changing ASOs, that inhibit forward splicing, and promote intron-backfolding for assisting backsplicing and circularization. Finally, deeper insight into how specific atherosclerosis-linked SNPs in ANRIL affect splice site choice 92 (e.g., through RNA-binding proteins), may allow to get a grip on deliberately affecting circularization.
(3) Proinflammatory signaling drives atherogenesis and various lncRNAs regulate inflammation-dependent gene expression in different cell types. For example, during nuclear factor kappa B signaling in macrophages, LincRNA-Cox2 represses numerous genes by scaffolding RelA-p50 into SWI/SNF complexes. 51 In contrast, PACER upregulates COX-2, a proatherogenic cyclooxygenase, by interfering with the formation of repressive p50:p50 homodimers, 66 and Lethe inhibits RelA binding to DNA. 47 Other lncRNAs are active in T cells or ECs: NRON scaffolds the cytoplasmic IQGAP1/NFAT1 protein complex, thereby restraining calcineurin from activating the proinflammatory NFAT1 transcription factor in T cells. 24, 97 In ECs, STEEL recruits the activating poly-adenosine diphosphate ribosylase PARP1 to KLF2 and eNOS. 71 Depleting PARP1 is known to limit atherosclerotic plaque growth, 98 suggesting that inhibiting STEEL could be interesting. Together, upregulating Lethe and downregulating lincRNA-Cox2, PACER, and THRIL may be therapeutically useful (see Refs. 99 and 100 for review on atherogenic inflammation).
Disease Therapy by Artificial (Nonnative) Designer lncRNAs
To achieve lncRNAs with novel functionality, endogenous RNA sequence can be altered, or synthetic constructs are overexpressed. These can contain sequence combinations not existing in endogenous RNA, or stem from in vitro evolution routines:
(1) Although microRNA sponging is not considered a common endogenous function for lncRNAs, therapeutically overexpressed lncRNAs are more abundant than endogenous RNAs and may very well become sponges. Such artificial sponges can be optimized by increasing microRNA-binding sites, and by optimally spacing them. 101 Furthermore, if target-matched sites are shortened from 8 to 6 nt, microRNA degradation happens instead of sponging, opening therapeutic possibilities even further. 16 circRNAs may become the superior type of sponges because circRNAs are more stable against cellular exoribonucleases than linear RNAs. 9, 10 (2) Artificial RNA aptamers, as high-affinity binders of biomolecules, constitute a large therapeutic class. Endogenous lncRNAs fold into secondary structures, and more so than mRNAs. 102 Notable are conserved stem-loop structures in protein-interaction interfaces. With a novel in vitro sequence evolution methods in development (e.g., SELEX with Pol θ CS13 ribonucleotidyl transferases that deliver random RNA libraries and tolerate 2′-functionalized ribonucleotides 103 ), it becomes tangible to engineer protein-or metabolite-binding RNAs, much like small molecules are classically used as protein-targeting "drugs." An alternative application of RNA aptamers is to bind surface receptors in diseased cells and confer cell entry of drugs and effectors fused to RNA. 104 (3) Therapeutically relevant peptides can be expressed from designer lncRNA: Although the vast majority of linear and circular lncRNAs are endogenously not translated to polypeptides by ribosomes, there are exceptions: small ORFs encoding micropeptides are known in lncRNAs, and some have cardiovascular relevance (LINC0094 8!myoregulin; SMIM6 !endoregulin; LOC100507537!DWORF). 105 Also, a tiny fraction of native circRNAs can be translated if noncoding RNA segments in the circle fold into internal ribosome entry sites (IRES) to drive translation initiation (circZNF609). 26 Therefore, one future therapeutic option would be to circularize mRNA to obtain stable expression of therapeutic proteins from a designer circRNA containing an artificial IRES sequence.
(4) Immunotherapy of atherosclerosis by boosting innate immune signaling: One future option for atherosclerosis therapy is to boost specific branches in innate-adaptive immune system cross-talk, a concept stemming from research on antitumor strategies (see Ref. 106 for overview). This may potentially supplement the more classical antiinflammatory strategies to fight atherosclerosis. 107 Recent insight shows that also noncoding RNA may have a place in immunotherapy: First, externally provided synthetic noncoding RNA or RNA analogs are already used as adjuvants to increase the immunogenicity of peptide-based vaccination, by virtue of their ability to stimulate cytoplasmic innate immunity receptors RIG-I and MDA5 as "nonself." [108] [109] [110] Vaccinations, such as with the tolerizing apoB100 epitope, 111 might in the future benefit. Controlling RIG-I signaling, as far as known from the cancer field, may well also be therapeutically useful for atherosclerosis therapy. The aim here may be to induce programmed cell death by natural killer cells, to enhance phagocytosis by dendritic cell subtypes, to leverage the contribution of specific T cell subtypes in resolving lesions, and to promote neoantigen presentation to lymphocytes. 112 A broad MDA-5 and RIG-I activation by RNA is, however, certainly not the goal, because this is known to promote proinflammatory signaling in ECs and macrophages 113 or osteogenic calcification in aortic VSMCs. 114 As of yet, too little is known about the cross-talk between innate 115 and adaptive immunity 116 in atherosclerosis. Therefore, it is open whether it would be beneficial to transfect synthetic noncoding (uncapped or circular) RNAs as therapeutic triggers of RIG-I 117,118 into specific protective immune cell types, or whether, oppositely, it is the reduction of endogenous RIG-I signaling that may bear protective effects.
Molecular Techniques for lncRNA-Based Therapy
In the following, we briefly describe different modern technologies to knockdown, overexpress, and study aberrantly 
Therapeutic Modulation of lncRNA Levels In Vivo
In the first place, identifying lncRNAs with potential therapeutic relevance necessitates finding animal orthologs of human disease-linked lncRNAs. In atherosclerosis, this can be straightforward (Malat1, Miat, Rncr3, H19), or more complicated (ANRIL 119 ), because evolutionary selective constraint for the majority of lncRNA sequences is modest at most, and exon-intron structure changes accordingly faster than for protein-coding genes. 120 If the genomic structure of an atherosclerosis-relevant locus is overall conserved but yields noncoding RNA with only limited conservation, humanizing synthetic disease-linked regions in mice with relevant human lncRNAs through knock-ins may be a viable approach. If mouse lncRNA orthologs exist, knockdown techniques can be directly executed, involving lncRNA depletion via the RNAi machinery (mostly in the cytoplasm), RNase-H1-type enzymes (also in the cell nucleus), or RNA-cutting ribozymes (►Fig. 2B). Conversely, lncRNA overexpression occurs from plasmids or viral vectors. For circRNA biogenesis from DNA vectors, in many studies, reverse complementary intronic repeats are routinely placed adjacent to circularizing exons, which support backsplicing through backfolding (see Refs. 9 and 10 for review). An interesting new concept are selfamplifying RNA "replicons," derived from disarmed, cytoplasmic, self-replicating RNA-alphaviruses, which can make RNA therapy permanent without the need for genome integration of RNA-generating vectors. 121 Another novel approach employs guide RNAs to target heterologous activator or repressor domains to lncRNA promoters, which causes up-/downregulation of transcription efficiency. 122 Apart from expression via vectors, lncRNAs can also be locally provided to the target tissue, which is the arterial lesion-containing vessel wall, by transfection of in vitroproduced RNA molecules: One problem of this approach is that routine solid-phase chemical RNA synthesis is still sizelimited (currently 100 nts). Thus, lncRNAs, due to their size, are often transcribed by T7 RNA polymerase in vitro. Also, RNA circularization is possible in vitro. Thereby, linear T7 transcripts are circularized, either chemically through artificial linkers (e.g., via phosphotriester or click chemistry) or enzymatically through 2′-5′ or 3′-5 backbone linkage (via T4 DNA/RNA ligases, tRNA ligases, or ribozymes such as group II intron derivatives) (see Ref. 123 for review). Recombinant expression in heterologous hosts (Escherichia coli, yeast) would allow higher linear or circular lncRNAs yield than achieved by in vitro transcription, but so far suffered from stability issues and heterogeneity of RNA ends. Novel unconventional bacterial hosts, such as the marine Rhodovulum sulfidophilum, circumvent some problems, as they secrete nucleic acids but do not contain RNases in their extracellular space. 124 Together, novel expression hosts, RNA affinity tags, and methods like exponential in vitro synthesis of RNA through polymerase chain transcription 125 allow producing sufficient amounts of high-quality RNA for therapy (see Ref. 126 for an overview).
Designing lncRNA Function by Modulating RNA Sequence
In addition to modifying lncRNA levels, a second therapeutic approach is to create designer lncRNAs, whose RNA sequence, structural motifs, or posttranscriptional modifications are purposely engineered. Enabling sequence modifications in vivo, the technical evolution of Cas enzymes has recently made a significant step forward. Instead of modifying DNA via the classical Cas9 enzymes, Cas13 nucleases were found to target RNA. In one application, Cas13 derivatives allow to purposefully destruct RNAs. 127, 128 But Cas13 derivatives also serve to modify RNA sequence when fusing Cas13 to the ADAR2 enzyme: The latter confers adenosine deamination to inosine in a target RNA, with inosine being functionally equivalent to guanosine in translation and splicing (termed REPAIR tool in ►Fig. 2B). 128 Linking other RNAmodifying enzymes to Cas13 has potential to modify target RNAs in different ways.
A range of artificial chemical RNA modifications (both at bases and in the phosphodiester backbone) have been chemically introduced in synthetic therapeutic nucleic acids, and benefits for therapy have been determined, mostly from experience with ASOs. Some modifications improve resistance against nucleases, increase potency, or improve pharmacokinetic properties and cellular uptake (see Ref. 129 for review). Covalent modifications, as used in ASOs, can theoretically be applied equally to in vitro synthesized lncRNAs, such as links to the ribose 2′ position (2′-fluoro, 2′-Omethoxyethyl, or cEt-constrained 2′-O-Ethyl). But to date, chemically modified lncRNAs have not yet been used for therapeutic purposes, in part because any modifications may negatively affect interactions with proteins or client RNAs. On the other hand, insight into the roles of some endogenously occurring posttranscriptional chemical modifications of RNAs (both coding and noncoding) are emerging, paving the field of "epitranscriptomics," as allusion to the so important concept of epigenomic control. For example, methylation (m 5 C, m 6 A), pseudouridylation (Ψ), and editing (deamination of A-to-I), known since more than 50 years, have more recently been functionally related to stability (also) of noncoding RNA, 130 to the formation of higher-order structure necessary for contact with proteins, 131, 132 to splicing, 133, 134 to RNA backbone rigidity 135 and base-pairing features, 136 and functional recognition of microRNA binding sites. 137, 138 But this knowledge has not yet been exploited for engineering lncRNA therapy.
Structure-Function Studies in Designer lncRNAs
In comparison to modulating RNA sequence and covalent modifications on RNA, designing RNA function through engineering secondary and tertiary RNA folds is even more complex. Although several native RNAs have evolved to regulate proteins, engineering a protein-activity-regulating lncRNA by bioinformatically designing RNA structure de novo is not yet possible. However, exploring native RNA: protein complexes with new structural methods (e.g. cryoEM), and through chemical probing, now even possibly inside living cells (PARIS, SHAPE-MaP), 139 will help to control how lncRNAs bind, scaffold, and regulate their molecular targets.
Hand-in-hand goes the development of novel technologies for profiling the molecular detail of lncRNA interactions with chromatin factors in DNA complexes, a major role of lncRNAs. Techniques for this structure-function analysis at a higher level include ChIRP, CHART, RAP, and ChOP (see Ref. 140 for an overview). Insight from these technologies is central because knowing the chromosomal lncRNA targets in disease-relevant cell types is necessary to achieve specificity in lncRNA therapy. 127, 128 Potential Side Effects during Systemic lncRNA Therapy and Therapeutic Implications If thoroughly studied, virtually every lncRNA becomes known to engage multiple effector mechanisms in cell type-specific manners. Consequently, side effects are likely in systemic and long-lasting therapy, as applying to atherosclerosis. For example, MALAT1 levels drop in plaques, 55 and Malat1 knockouts developed atherosclerosis, 81 suggesting that therapeutic upregulation of MALAT1 might ameliorate disease. On the other hand, MALAT1 is upregulated in cancer cells and is cancer-promoting. 84 Such dichotomy necessitates tools for conditional lncRNA delivery. Similar disastrous side effects and dangers regarding cancer development and metabolic syndrome apply to circHIPK3 and Gas5.
To avoid these side effects, and also to counteract offtargeting, conditional delivery schemes are necessary: For guiding their expression in atherosclerotic lesions within the vascular wall, synthetic lncRNAs can be conjugated to plaque-homing peptides (e.g., Ac2-26/LyP-1), 141 antibodies or lipid/lipoprotein carriers (high-density lipoprotein), 142 or be packaged in lipid vesicles with targeting cues on their surface (e.g., CCR receptors). The most modern relevant approach for conditional expression in biomedicine is localized delivery through photo-and optoacoustic approaches. 143 An alternative is to elute RNA from coated stents or from perivascular hydrogels. Not last, lncRNA activity can, in principle, be controlled by laser light, when lncRNA are synthesized with optogenetically regulatable backbones or caging groups, 144 but optogenetic control of lncRNAs has not yet been performed in therapy in vivo, so far.
Conclusion
To date, around 70 clinical trials are known to center on RNA therapeutics, and these exclusively involve small interfering ASOs/siRNAs and therapeutic mRNAs, but not yet lncRNAs. 145 Despite the relatively slow translation of RNAcentered therapy into the clinics, 145 RNA therapeutics is gaining renewed interest, not last through novel insights into lncRNA biology. Further, the ease by which candidate lncRNA can be screened and optimized in their interaction with disease targets surpasses the work with classical small molecule drugs whose targeting to proteins is complex to predict, control, and modify. Any future therapy with lncRNAs will benefit from insight into RNA mass production, chemical modifications, and cellular delivery schemes developed for ASOs/siRNAs over the last decades. As many of the previously unknown cell subtypes that contribute to plaque growth currently become molecularly characterized by novel methods like mass spectrometric cytometry, [146] [147] [148] and as methods for RNA chromatin profiling at single-cell resolution from limited tissue sources emerge, 149 the vision of a highly specific lncRNA-centered therapy in atherosclerosis is materializing, possibly sooner than expected.
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